Drug Profile

123BB zT2

Alternative Names: 123BB-zT2

Latest Information Update: 01 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wellington Zhaotai Therapies
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

26 Mar 2025 123BB zT2 is available for licensing as of 26 Mar 2025. https://www.wellingtonzhaotai.com/business-development
26 Mar 2025 Wellington Zhaotai Therapies has patent protection for CAR T-cell construct with unique, co-stimulatory domain (Wellington Zhaotai Therapies pipeline, March 2025)
26 Mar 2025 Preclinical trials in Acute myeloid leukaemia in New Zealand (Parenteral) (Wellington Zhaotai Therapies pipeline, March 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com